vs
Side-by-side financial comparison of Stryker Corporation (SYK) and TELUS CORP (TU). Click either name above to swap in a different company.
Stryker Corporation is the larger business by last-quarter revenue ($7.2B vs $3.7B, roughly 1.9× TELUS CORP). Stryker Corporation runs the higher net margin — 11.8% vs -4.8%, a 16.7% gap on every dollar of revenue. On growth, Stryker Corporation posted the faster year-over-year revenue change (11.4% vs 2.2%).
The Stryker is a family of eight-wheeled armored fighting vehicles derived from the Canadian LAV III, which in turn derived from the Swiss Mowag Piranha. Stryker vehicles are produced by General Dynamics Land Systems-Canada (GDLS-C) for the United States Army in a plant in London, Ontario. It has four-wheel drive (8×4) and can be switched to all-wheel drive (8×8).
TELUS CORPTUEarnings & Financial Report
Telus Corporation is a Canadian publicly traded holding company and conglomerate, headquartered in Vancouver, British Columbia, which is the parent company of several subsidiaries: Telus Communications offers telephony, television, data and Internet services; Telus Mobility offers wireless services; Telus Health operates companies that provide health products and services; and Telus Digital operates worldwide, providing multilingual customer service outsourcing and digital IT services. Telus ...
SYK vs TU — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.2B | $3.7B |
| Net Profit | $849.0M | $-178.8M |
| Gross Margin | 64.5% | 90.2% |
| Operating Margin | 25.2% | 3.4% |
| Net Margin | 11.8% | -4.8% |
| Revenue YoY | 11.4% | 2.2% |
| Net Profit YoY | 55.5% | -210.9% |
| EPS (diluted) | $2.20 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.2B | — | ||
| Q3 25 | $6.1B | — | ||
| Q2 25 | $6.0B | $3.7B | ||
| Q1 25 | $5.9B | — | ||
| Q4 24 | $6.4B | — | ||
| Q3 24 | $5.5B | — | ||
| Q2 24 | $5.4B | $3.6B | ||
| Q1 24 | $5.2B | — |
| Q4 25 | $849.0M | — | ||
| Q3 25 | $859.0M | — | ||
| Q2 25 | $884.0M | $-178.8M | ||
| Q1 25 | $654.0M | — | ||
| Q4 24 | $546.0M | — | ||
| Q3 24 | $834.0M | — | ||
| Q2 24 | $825.0M | $161.3M | ||
| Q1 24 | $788.0M | — |
| Q4 25 | 64.5% | — | ||
| Q3 25 | 63.6% | — | ||
| Q2 25 | 63.8% | 90.2% | ||
| Q1 25 | 63.8% | — | ||
| Q4 24 | 64.9% | — | ||
| Q3 24 | 64.0% | — | ||
| Q2 24 | 63.0% | 87.9% | ||
| Q1 24 | 63.6% | — |
| Q4 25 | 25.2% | — | ||
| Q3 25 | 18.7% | — | ||
| Q2 25 | 18.5% | 3.4% | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 9.0% | — | ||
| Q3 24 | 19.7% | — | ||
| Q2 24 | 19.4% | 13.7% | ||
| Q1 24 | 18.5% | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 14.2% | — | ||
| Q2 25 | 14.7% | -4.8% | ||
| Q1 25 | 11.1% | — | ||
| Q4 24 | 8.5% | — | ||
| Q3 24 | 15.2% | — | ||
| Q2 24 | 15.2% | 4.4% | ||
| Q1 24 | 15.0% | — |
| Q4 25 | $2.20 | — | ||
| Q3 25 | $2.22 | — | ||
| Q2 25 | $2.29 | — | ||
| Q1 25 | $1.69 | — | ||
| Q4 24 | $1.41 | — | ||
| Q3 24 | $2.16 | — | ||
| Q2 24 | $2.14 | — | ||
| Q1 24 | $2.05 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.0B | $2.7B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $22.4B | $11.8B |
| Total Assets | $47.8B | $44.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.0B | — | ||
| Q3 25 | $3.3B | — | ||
| Q2 25 | $2.4B | $2.7B | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $3.7B | — | ||
| Q3 24 | $3.9B | — | ||
| Q2 24 | $1.9B | $676.7M | ||
| Q1 24 | $2.3B | — |
| Q4 25 | $22.4B | — | ||
| Q3 25 | $21.8B | — | ||
| Q2 25 | $21.2B | $11.8B | ||
| Q1 25 | $20.9B | — | ||
| Q4 24 | $20.6B | — | ||
| Q3 24 | $20.1B | — | ||
| Q2 24 | $19.8B | $12.4B | ||
| Q1 24 | $19.2B | — |
| Q4 25 | $47.8B | — | ||
| Q3 25 | $47.1B | — | ||
| Q2 25 | $46.3B | $44.3B | ||
| Q1 25 | $46.0B | — | ||
| Q4 24 | $43.0B | — | ||
| Q3 24 | $43.8B | — | ||
| Q2 24 | $39.1B | $41.8B | ||
| Q1 24 | $39.4B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1B | $851.2M |
| Free Cash FlowOCF − Capex | $1.9B | — |
| FCF MarginFCF / Revenue | 26.1% | — |
| Capex IntensityCapex / Revenue | 3.7% | — |
| Cash ConversionOCF / Net Profit | 2.52× | — |
| TTM Free Cash FlowTrailing 4 quarters | $4.3B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.1B | $851.2M | ||
| Q1 25 | $250.0M | — | ||
| Q4 24 | $1.9B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $633.0M | $1.0B | ||
| Q1 24 | $204.0M | — |
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $928.0M | — | ||
| Q1 25 | $127.0M | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $481.0M | — | ||
| Q1 24 | $37.0M | — |
| Q4 25 | 26.1% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 15.4% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 25.9% | — | ||
| Q3 24 | 23.7% | — | ||
| Q2 24 | 8.9% | — | ||
| Q1 24 | 0.7% | — |
| Q4 25 | 3.7% | — | ||
| Q3 25 | 3.1% | — | ||
| Q2 25 | 3.0% | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 2.8% | — | ||
| Q1 24 | 3.2% | — |
| Q4 25 | 2.52× | — | ||
| Q3 25 | 1.79× | — | ||
| Q2 25 | 1.26× | — | ||
| Q1 25 | 0.38× | — | ||
| Q4 24 | 3.54× | — | ||
| Q3 24 | 1.77× | — | ||
| Q2 24 | 0.77× | 6.28× | ||
| Q1 24 | 0.26× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SYK
| Medical | $1.3B | 18% |
| Endoscopy | $1.1B | 16% |
| Traumaand Extremities | $1.1B | 15% |
| Instruments | $925.0M | 13% |
| Knees | $749.0M | 10% |
| Neuro Cranial | $669.0M | 9% |
| Neurovascular | $539.0M | 8% |
| Hips | $499.0M | 7% |
| Other Orthopaedics | $267.0M | 4% |
| Spine | $8.0M | 0% |
TU
Segment breakdown not available.
